Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1101 studies found for:    ALA
Show Display Options
Rank Status Study
1 Not yet recruiting The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors
Condition: Central Nervous System Tumor, Pediatric
Intervention: Drug: 5ALA
2 Unknown  A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Condition: Glioma
Intervention: Drug: 5-Aminolevuline Acid
3 Unknown  Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
Condition: Glioma
Intervention: Drug: 5-Aminolevuline Acid
4 Recruiting Fluorescence and Glioma Heterogeneity
Condition: Malignant Gliomas
Intervention: Procedure: ALA Test group
5 Completed Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood
Conditions: Insomnia;   Nocturnal Awakening;   Irritability;   Coping Behavior;   Stress
Interventions: Dietary Supplement: 5-Aminolevulinic Acid (5-ALA);   Dietary Supplement: Placebo
6 Active, not recruiting Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Condition: Glioblastoma
Interventions: Drug: 5-ALA;   Drug: Gliadel wafers
7 Recruiting 5-ALA in Recurrent Glioma
Condition: Glioma
Intervention: Drug: 5-ala
8 Withdrawn A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer
Condition: Lung Cancer in Normal and Malignant Tumors
Intervention: Drug: ALA-induced Fluorescence
9 Completed An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
Conditions: Obesity;   Weight Loss;   Schizophrenia
Intervention: Dietary Supplement: Alpha Lipoic Acid
10 Withdrawn A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Condition: Brain Neoplasms
Intervention: Drug: 5-aminolevulinic acid
11 Recruiting Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel
Condition: Actinic Keratosis
Interventions: Drug: METHYLAMINOLEVULINATE HYDROCHLORIDE;   Drug: AMINOLEVULINIC ACID HYDROCHLORIDE
12 Completed Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
Condition: Actinic Keratosis
Interventions: Drug: Vehicle;   Drug: BF-200 ALA
13 Completed Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans
Conditions: Overweight;   Hypercholesterolemia
Interventions: Dietary Supplement: n-3 PUFA free olive oil;   Dietary Supplement: linseed oil
14 Completed This Study Aims to Evaluate the Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy (PDT)
Condition: Actinic Keratosis
Interventions: Drug: BF-200 ALA;   Drug: MAL
15 Completed
Has Results
Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)
Condition: Multiple Actinic Keratoses
Interventions: Drug: BF-200 ALA cream;   Drug: MAL cream
16 Terminated A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
Conditions: Malignant Glioma;   Glioma;   Glioblastoma;   Glioblastoma Multiforme;   Astrocytoma
Intervention: Drug: Aminolevulinic Acid
17 Unknown  Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery
Conditions: Primary Malignant Neoplasm of Nervous System;   Glioma;   Glioblastoma;   Metastasis
Interventions: Procedure: Interventional arm;   Procedure: Control arm
18 Completed Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Condition: Brain Tumors
Intervention: Drug: Aminolevulinic Acid
19 Completed A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine
Condition: Transitional Cell Carcinoma of the Bladder
Intervention: Drug: Amino levulinic Acid
20 Recruiting Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)
Conditions: Actinic Keratosis;   Natural Daylight Photodynamic Therapy
Interventions: Drug: Aminolevulinic Acid;   Drug: Methyl 5-aminolevulinate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.